Literature DB >> 15507622

Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors.

Ziv Sandalon1, Elizabeth M Bruckheimer, Kurt H Lustig, Linda C Rogers, Richard W Peluso, Haim Burstein.   

Abstract

This study evaluated and compared delivery of the tumor necrosis factor alpha receptor (TNFR)-immunoglobulin G1 (IgG1) Fc fusion (TNFR:Fc) gene to the lung by single and repeat administrations of multiple pseudotyped adeno-associated virus (AAV) vectors as a means for achieving systemic distribution of the soluble TNFR:Fc protein. A single endotracheal administration of AAV[2/5]cytomegalovirus (CMV)-TNFR:Fc vector (containing the AAV2 inverted terminal repeats and AAV5 capsid) to the rat lung resulted in long-term, high levels of serum TNFR:Fc protein that gradually declined over a period of 8 months. Endotracheal delivery of AAV[2/1]CMV-TNFR:Fc resulted in serum TNFR:Fc protein levels that were detectable for at least 4 months but were 10-fold lower than that of the AAV[2/5] vector. In contrast, secretion of the TNFR:Fc protein following pulmonary delivery of AAV[2/2]CMV-TNFR:Fc vector was very inefficient, and the protein was detected in the blood only when an airway epithelial cell-specific promoter, CC10, was substituted for the CMV enhancer/promoter to control transgene expression. In the context of AAV[2/5], the CC10 promoter was as efficient as CMV enhancer/promoter in generating similar levels of systemic TNFR:Fc protein, suggesting that this protein is secreted primarily from the airway epithelium. In mice, comparable long-term secretion of TNFR:Fc protein was demonstrated after AAV[2/2] and AAV[2/5] delivery, although the kinetics of transduction appeared to be different. All pseudotyped AAV vectors elicited serum anti-AAV capsid-neutralizing antibody responses, but these did not prevent lung transduction and efficient secretion of TNFR:Fc protein to the circulation following readministration with AAV[2/5]. These results highlight the potential utility of AAV vectors containing serotype 5 capsid to deliver and redeliver genes of secreted proteins to the lung to achieve long-term systemic protein expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507622      PMCID: PMC525098          DOI: 10.1128/JVI.78.22.12355-12365.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques.

Authors:  Anne C Fischer; Suzanne E Beck; Carolina I Smith; Beth L Laube; Frederic B Askin; Sandra E Guggino; Robert J Adams; Terence R Flotte; William B Guggino
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

2.  Free DNA ends are essential for concatemerization of synthetic double-stranded adeno-associated virus vector genomes transfected into mouse hepatocytes in vivo.

Authors:  Hiroyuki Nakai; Sally Fuess; Theresa A Storm; Leonard A Meuse; Mark A Kay
Journal:  Mol Ther       Date:  2003-01       Impact factor: 11.454

3.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

5.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

6.  Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.

Authors:  Rita Sarkar; Renee Tetreault; Guangping Gao; Lili Wang; Peter Bell; Randy Chandler; James M Wilson; Haig H Kazazian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

7.  Identification of PDGFR as a receptor for AAV-5 transduction.

Authors:  Giovanni Di Pasquale; Beverly L Davidson; Colleen S Stein; Inês Martins; Dominic Scudiero; Anne Monks; John A Chiorini
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

8.  Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Authors:  Terence R Flotte; Pamela L Zeitlin; Thomas C Reynolds; Alison E Heald; Patty Pedersen; Suzanne Beck; Carol K Conrad; Lois Brass-Ernst; Margaret Humphries; Kevin Sullivan; Randall Wetzel; George Taylor; Barrie J Carter; William B Guggino
Journal:  Hum Gene Ther       Date:  2003-07-20       Impact factor: 5.695

9.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Authors:  Richard B Moss; David Rodman; L Terry Spencer; Moira L Aitken; Pamela L Zeitlin; David Waltz; Carlos Milla; Alan S Brody; John P Clancy; Bonnie Ramsey; Nicole Hamblett; Alison E Heald
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  Cloning of infectious adeno-associated virus genomes in bacterial plasmids.

Authors:  C A Laughlin; J D Tratschin; H Coon; B J Carter
Journal:  Gene       Date:  1983-07       Impact factor: 3.688

View more
  13 in total

Review 1.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

Review 2.  Molecular mechanisms and treatment of radiation-induced lung fibrosis.

Authors:  Nian-Hua Ding; Jian Jian Li; Lun-Quan Sun
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

3.  Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.

Authors:  Susumu Sakata; Djamel Lebeche; Naoya Sakata; Yuri Sakata; Elie R Chemaly; Li Fan Liang; Tsuyoshi Tsuji; Yoshiaki Takewa; Federica del Monte; Richard Peluso; Krisztina Zsebo; Dongtak Jeong; Woo Jin Park; Yoshiaki Kawase; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2007-01-10       Impact factor: 5.000

4.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

5.  Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation.

Authors:  Ronen Beeri; Miguel Chaput; J Luis Guerrero; Yoshiaki Kawase; Chaim Yosefy; Suzan Abedat; Ioannis Karakikes; Charlotte Morel; Ashley Tisosky; Suzanne Sullivan; Mark D Handschumacher; Dan Gilon; Gus J Vlahakes; Roger J Hajjar; Robert A Levine
Journal:  Circ Heart Fail       Date:  2010-07-15       Impact factor: 8.790

6.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

7.  Analysis of adeno-associated virus progenitor cell transduction in mouse lung.

Authors:  Xiaoming Liu; Meihui Luo; Chenhong Guo; Ziying Yan; Yujiong Wang; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2008-11-25       Impact factor: 11.454

8.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

Authors:  Jodi L McBride; Ryan L Boudreau; Scott Q Harper; Patrick D Staber; Alex Mas Monteys; Inâs Martins; Brian L Gilmore; Haim Burstein; Richard W Peluso; Barry Polisky; Barrie J Carter; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-08       Impact factor: 11.205

9.  AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression.

Authors:  J A Cirelli; C H Park; K MacKool; M Taba; K H Lustig; H Burstein; W V Giannobile
Journal:  Gene Ther       Date:  2008-12-11       Impact factor: 5.250

10.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Authors:  Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark
Journal:  Nat Med       Date:  2009-05-17       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.